The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study

被引：0

作者：

Akito Nozaki

Masanori Atsukawa

Chisa Kondo

Hidenori Toyoda

Makoto Chuma

Makoto Nakamuta

Haruki Uojima

Koichi Takaguchi

Hiroki Ikeda

Tsunamasa Watanabe

Shintaro Ogawa

Norio Itokawa

Taeang Arai

Atsushi Hiraoka

Toru Asano

Shinichi Fujioka

Tadashi Ikegami

Toshihide Shima

Chikara Ogawa

Takehiro Akahane

Noritomo Shimada

Shinya Fukunishi

Hiroshi Abe

Akihito Tsubota

Takuya Genda

Hironao Okubo

Shigeru Mikami

Asahiro Morishita

Akio Moriya

Joji Tani

Yoshihiko Tachi

Naoki Hotta

Toru Ishikawa

Takeshi Okanoue

Yasuhito Tanaka

Takashi Kumada

Katsuhiko Iwakiri

Shin Maeda

机构：

[1] Yokohama City University Medical Center,Gastroenterological Center

[2] Nippon Medical School,Department of Internal Medicine, Division of Gastroenterology and Hepatology

[3] Ogaki Municipal Hospital,Department of Gastroenterology

[4] National Hospital Organization Kyushu Medical Center,Department of Gastroenterology, Internal Medicine

[5] Kitasato University School of Medicine,Department of Hepatology

[6] Kagawa Prefectural Central Hospital,Department of Internal Medicine

[7] St. Marianna University School of Medicine,Department of Virology and Liver Unit

[8] Nagoya City University,Division of Gastroenterology, Department of Internal Medicine

[9] Graduate School of Medical Sciences,Division of Gastroenterology, Department of Internal Medicine

[10] Nippon Medical School Chiba Hokusoh Hospital,Gastroenterology Center

[11] Nippon Medical School Musashikosugi Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[12] Ehime Prefectural Central Hospital,Department of Gastroenterology

[13] Tokyo Metropolitan Bokutoh Hospital,Department of Gastroenterology and Hepatology

[14] Okayama Saiseikai General Hospital,Department of Gastroenterology and Hepatology

[15] Tokyo Medical University Ibaraki Medical Center,Department of Gastroenterology

[16] Saiseikai Suita Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[17] Takamatsu Red Cross Hospital,Second Department of Internal Medicine

[18] Japanese Red Cross Ishinomaki Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[19] Otakanomori Hospital,Core Research Facilities for Basic Science

[20] Osaka Medical College,Department of Gastroenterology

[21] Shinmatsudo Central General Hospital,Department of Gastroenterology

[22] The Jikei University School of Medicine,Division of Gastroenterology, Department of Internal Medicine

[23] Juntendo Shizuoka University Hospital,Department of Gastroenterology

[24] Juntendo Nerima University Hospital,Department of Gastroenterology

[25] Kikkoman General Hospital,Department of Internal Medicine

[26] Kagawa University Graduate School of Medicine,Division of Hepatology, Department of Internal Medicine

[27] Mitoyo General Hospital,Department of Hepatology

[28] Yashima General Hospital,Department of Gastroenterology

[29] Bantane Hospital,undefined

[30] Fujita Health University School of Medicine,undefined

[31] Masuko Memorial Hospital,undefined

[32] Saiseikai Niigata Daini Hospital,undefined

[33] Yokohama City University Graduate School of Medicine,undefined

来源：

Hepatology International | 2020年 / 14卷

关键词：

Glecaprevir; Pibrentasvir; Chronic hepatitis C; Refractory factors; Multicenter study;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：225 / 238

页数：13

共 50 条

[21] REAL-WORLD EXPERIENCE OF GLECAPREVIR/PIBRENTASVIR TREATMENT IN JAPANESE ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY
Mizuochi, Tatsuki
Iwama, Itaru
Inui, Ayano
Ito, Yoshinori
Takaki, Yugo
Mushiake, Sotaro
Tokuhara, Daisuke
Ishige, Takashi
Ito, Koichi
Murakami, Jun
Hishiki, Haruka
Mikami, Hitoshi
Bessho, Kazuhiko
Kato, Ken
Yasuda, Ryosuke
Yamashita, Yushiro
Tanaka, Yasuhito
Tajiri, Hitoshi
HEPATOLOGY, 2022, 76 : S1524 - S1525
[22] Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry
Berg, Thomas
Naumann, Uwe
Stoehr, Albrecht
Sick, Christoph
John, Christine
Teuber, Gerlinde
Schiffelholz, Willibold
Mauss, Stefan
Lohmann, Kristina
Koenig, Bettina
Pangerl, Andreas
Niederau, Claus
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (08) : 1052 - 1059
[23] Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study
Morita, Atsuhiro
Tamaki, Nobuharu
Kobashi, Haruhiko
Mori, Nami
Tsuji, Keiji
Takaki, Shintaro
Hasebe, Chitomi
Akahane, Takehiro
Ochi, Hironori
Mashiba, Toshie
Urawa, Naohito
Fujii, Hideki
Mitsuda, Akeri
Kondo, Masahiko
Ogawa, Chikara
Uchida, Yasushi
Narita, Ryoichi
Marusawa, Hiroyuki
Kubotsu, Yoshihito
Matsushita, Tomomichi
Shigeno, Masaya
Yoshida, Hideo
Tanaka, Katsuaki
Okamoto, Eisuke
Kasai, Toyotaka
Ishii, Toru
Okada, Kazuhiko
Kurosaki, Masayuki
Izumi, Namiki
JGH OPEN, 2024, 8 (04):
[24] Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
Lampertico, Pietro
Carrion, Jose A.
Curry, Michael
Turnes, Juan
Cornberg, Markus
Negro, Francesco
Brown, Ashley
Persico, Marcello
Wick, Nicole
Porcalla, Ariel
Pangerl, Andreas
Crown, Eric
Larsen, Lois
Yu, Yao
Wedemeyer, Heiner
JOURNAL OF HEPATOLOGY, 2020, 72 (06) : 1112 - 1121
[25] Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan
Chiu, Wen-Nan
Hung, Chao-Hung
Lu, Sheng-Nan
Chen, Mei-Yen
Tung, Shui-Yi
Wei, Kuo-Liang
Lu, Chung-Kuang
Chen, Chien-Hung
Hu, Tsung-Hui
Hu, Jin-Hung
Chen, Wei-Ming
Chang, Te-Sheng
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 866 - 872
[26] Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study
D'Ambrosio, R.
Pasulo, L.
Puoti, M.
Schiavini, M.
Vigano, P.
Vinci, M.
Menzaghi, B.
Zuin, M. G.
Soria, A.
Spinetti, A.
Aghemo, A.
Rumi, M. G.
Uberti-Foppa, C.
Pan, A.
Spinelli, O.
Monforte, A. D'arminio
Capretti, A.
Colli, A.
Colombo, A.
Spinzi, G.
Centenaro, R.
Buscarini, E.
Soffredini, R.
Borghi, M.
Colpani, M.
Lazzaroni, S.
Maggiolo, F.
Gori, A.
Del Poggio, P.
Giorgini, A.
Morini, L.
Pigozzi, M. G.
Dibenedetto, C.
Giglio, O.
Magni, C. F.
Noventa, F.
Lampertico, P.
Fagiuoli, S.
JOURNAL OF HEPATOLOGY, 2018, 68 : S65 - S65
[27] The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
Yaras, Serkan
Demir, Mehmet
Barutcu, Sezgin
Yildirim, Abdullah Emre
Gurel, Selim
Ucbilek, Enver
Kurtulmus, Ilkce Akgun
Kayhan, Meral Akdogan
Vatansever, Sezgin
Adanir, Haydar
Danis, Nilay
Duman, Serkan
Turan, Ilker
Ari, Derya
Kose, Sukran
Alkim, Huseyin
Harputluoglu, Muhsin Murat
Dilber, Feyza
Akyildiz, Murat
Cosar, Arif Mansur
Durak, Serdar
Sirin, Goktug
Kefeli, Ayse
Gokcan, Hale
Avcioglu, Ufuk
Ayyildiz, Talat
Sezgin, Orhan
Akarsu, Mesut
Dincer, Dinc
Guzelbulut, Fatih
Gunsar, Fulya
Akarca, Ulus Salih
Idilman, Ramazan
HEPATOLOGY FORUM, 2023, 4 (03): : 92 - 96
[28] Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study
Ogawa, Eiichi
Furusyo, Norihiro
Nakamuta, Makoto
Nomura, Hideyuki
Satoh, Takeaki
Takahashi, Kazuhiro
Koyanagi, Toshimasa
Kajiwara, Eiji
Dohmen, Kazufumi
Kawano, Akira
Ooho, Aritsune
Azuma, Koichi
Kato, Masaki
Shimoda, Shinji
Hayashi, Jun
HEPATOLOGY RESEARCH, 2019, 49 (06) : 617 - 626
[29] Real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: updated data from the German Hepatitis C-Registry
Cornberg, M.
Naumann, U.
Stoehr, A.
Sick, C.
Teuber, G.
Schiffelholz, W.
Mauss, S.
Lohmann, K.
Kleine, H.
Pangerl, A.
Mueller, T.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 197 - 198
[30] First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry
Berg, T.
Naumann, U.
Stoehr, A.
Sick, C.
Teuber, G.
Schiffelholz, W.
Mauss, S.
Hettinger, J.
Kleine, H.
Pangerl, A.
Niederau, C.
JOURNAL OF HEPATOLOGY, 2018, 68 : S37 - S37

← 1 2 3 4 5 →